
August 16, 2024
UNC Lineberger provides $1.3 million in developmental research grants
More than $1.3 million in UNC Lineberger developmental research grants were awarded to 13 faculty members and one postdoctoral trainee this spring.
August 16, 2024
More than $1.3 million in UNC Lineberger developmental research grants were awarded to 13 faculty members and one postdoctoral trainee this spring.
July 2, 2024
NIH Director Monica Bertagnolli, MD, wrote about research led by UNC Lineberger’s Channing Der, PhD, and Adrienne Cox, PhD, that provided the most comprehensive molecular portrait of the workings of KRAS.
July 2, 2024
The UNC RNA Discovery Center held its inaugural retreat to bring together its members and trainees to present and discuss RNA science being conducted across UNC-Chapel Hill and beyond.
June 28, 2024
UNC Lineberger’s 47th annual scientific symposium featured 17 presentations from faculty at UNC Lineberger and institutions across the United States.
June 6, 2024
UNC Lineberger researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene, and how its activities impact pancreatic cancer outcomes.
June 6, 2024
May 28, 2024
UNC and UNC Lineberger researchers and trainees will be presenting talks and participating in scientific and educational panels and discussions on the latest cancer research at the ASCO Annual Meeting.
April 30, 2024
For Siddharth Sheth, DO, MPH, he knew UNC was the place for him when he pursued his first faculty position in medicine. However, it wasn’t just UNC that shaped his medical career. When Sheth’s mom was diagnosed with cancer and later relapsed, he knew oncology was the right path for him.
March 13, 2024
UNC Lineberger researchers have developed a molecule that is much more effective than a previously identified molecule at activating a biological pathway and spurring a strong anti-cancer immune response in preclinical studies.
March 4, 2024
The grant will support the first metastatic pancreatic cancer trial in the country to evaluate whether selecting treatment by tumor subtype will help patients match to more effective first-line therapies.